Clinical Trials
3 trialsNCT03535740 2025-07-31
ALTA-2
Takeda
Phase 2 Completed
NCT03410108 2024-05-08
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 2 Completed
NCT02094573 2021-03-15
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Takeda
Phase 2 Completed